Antibodies

Polyclonal antibody to bacterial transglutaminase (BTG, MTG)



Order
Quantity
Price
Status
200 µg 365 € available


Documents
Art. No. A145
Host Rabbit (number SY7957)
Immunogen Microbial (bacterial) transglutaminase (full length protein) from Streptomyces mobaraensis recombinantly produced in E. coli (T001).
Specificity Antibody reacts specifically with microbial (bacterial) transglutaminase and Protransglutaminase from Streptomyces mobaraensis in native or denatured form.
Formulation The antibody is lyophilized from 200 μL PBS pH 7.2, 2 mg/mL human serum albumin, azide free.
Working dilutions Optimal dilutions should be determined by the end user.
E. g. for Western-Blotting: 1 / 500 to 1 / 5,000 should be suitable
Storage Stable for a minimum of 2 years at –20°C as lyophilized powder
Delivery at ambient temperature is possible
Reference(s) Kaufmann et al., Food Addit. Contam.: Part A 2012, 29:1364-73;
Schloegl et al., Eur. J. Pharm. Biopharm. 2012, 80:282-8
Note Polyclonal antibody to MTG A145 replaces Polyclonal antibody A019 which is sold out.

INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Team-Assistenz (w/m/d) in Teilzeit gesucht
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France